原发性肝癌手术联合放疗的近期研究进展

doi:10.3760/cma.j.cn113030-20200829-00442

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Surgical resection is the main radical treatment of early and mid-stage primary liver cancer (PLC), but the high postoperative recurrence rate is the main factor affecting the curative effect. With recent advancement in techniques, the efficacy and safety of radiation therapy for PLC have been widely proven. In this review, we will investigate the combination of surgery and radiation therapy, covering the topics of preoperative or postoperative radiotherapy for PLC with portal vein tumor thrombus, postoperative adjuvant radiotherapy in PLC with narrow surgical margin or microvascular invasion, stereotactic body radiation therapy as a bridge to liver transplantation, radiotherapy in conversion to resectability for intrahepatic inoperable PLC. Despite radiation therapy is one of the effective therapeutic options for PLC, there is still a compelling need for prospective, randomized, controlled phase Ⅲ trials to acquire high-levelclinical evidence for confirming the role of radiation therapy in the treatment of PLC.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yang Yongqiang
	Chen Wei
	Tian Ye

Key words： Liver neoplasm/surgery Liver neoplasm/radiotherapy Research progress

Received: 29 August 2020

Fund:Jiangsu Medical Innovation Team (CXDT-37);Suzhou Introduced Project of Clinical Medical Expert Team (SZYJTD201803)

Corresponding Authors: Chen Wei, Email:chenwei1971@vip.163.com;Tian Ye, Email:dryetian@126.com

Cite this article:

Yang Yongqiang,Chen Wei,Tian Ye. Recent research progress on surgery combined with radiation therapy for primary liver cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(7): 744-747.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200829-00442 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I7/744

[1] Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462. DOI:10.1056/NEJMra1713263.
[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314. DOI:10.1016/S0140-6736(18)30010-2.
[3] 中华医学会放射肿瘤学分会,中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会,中国研究型医院学会放射肿瘤学分会肝癌学组.2016年原发性肝癌放疗共识[J]. 中华放射肿瘤学杂志,2016, 25(11):1141-1150. DOI:10.3760/cma.j.issn.1004-4221.2016.11.001.
Radiation Oncology Branch of the Chinese Medical Association, Expert Committee on Liver Cancer and Digestive System of China Institute of Biomedical Engineering, Liver Cancer Research Group of Radiation Oncology Branch of China Research Hospital. Consensus on radiation therapy for primary liver cancer in 2016[J]. Chin J Radiat Oncol, 2016, 25(11):1141-1150. DOI:10.3760/cma.j.issn.1004-4221.2016.11.001.
[4] Zhou. J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in china (2017 edition)[J]. Liver Cancer, 2018, 7(3):235-260. DOI:10.1159/000488035.
[5] Cheng S, Chen M, Cai J, et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 edition)[J]. Liver Cancer, 2020, 9(1):28-40. DOI:10.1159/000503685.
[6] 杨咏强,田野. 原发性肝癌放疗的指南推荐解读[J]. 中华放射肿瘤学杂志,2018, 27(5):538-541. DOI:10.3760/cma.j.issn.1004-4221.2018.05.021.
Yang YQ, Tian Y. A review of updated guidelines for radiotherapy for primary liver cancer[J]. Chin J Radiat Oncol, 2018, 27(5):538-541. DOI:10.3760/cma.j.issn.1004-4221.2018.05.021.
[7] Lu J, Zhang XP, Zhong BY, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis:comparing east and west[J]. Lancet Gastroenterol Hepatol, 2019, 4(9):721-730. DOI:10.1016/S2468-1253(19)30178-5.
[8] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822):1245-1255. DOI:10.1016/S0140-6736(11)61347-0.
[9] 程树群,吴孟超,陈汉,等. 癌栓分型对肝细胞性肝癌合并门静脉癌栓治疗及预后的指导意义[J]. 中华医学杂志, 2004, 84(1):3-5. DOI:10.3760/j:issn:0376-2491.2004.01.002.
Cheng SQ, Wu MC, Chen H, et al. Significance of typing of tumor thrombi in determination of treatment and assessment of prognosis of hepatocellular carcinoma with tumor thrombi in the portal vein[J]. Natl Med J China, 2004, 84(1):3-5. DOI:10.3760/j:issn:0376-2491.2004.01.002.
[10] Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24):2141-2151. DOI:10.1200/JCO.18.02184.
[11] Sun J, Yang L, Shi J, et al. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus:An open-label randomized controlled trial[J]. Radiother Oncol, 2019, 140(1):20-25. DOI:10.1016/j.radonc.2019.05.006.
[12] Wang WH, Wang Z, Wu JX, et al. Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels[J]. Liver Int, 2015, 35(12):2603-2610. DOI:10.1111/liv.12857.
[13] Jia AY, Wu JX, Zhao YT, et al. Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma[J]. J Gastrointest Oncol, 2015, 6(2):126-133. DOI:10.3978/j.issn.2078-6891.2014.102.
[14] Zheng X, Chen B, Wu JX, et al. Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels[J]. Cancer Manag Res, 2018, 10:3973-3981. DOI:10.2147/CMAR. S172940.
[15] Rodríguez-Perálvarez M, Luong TV, Andreana L, et al. A systematic review of microvascular invasion in hepatocellular carcinoma:diagnostic and prognostic variability[J]. Ann Surg Oncol, 2013, 20(1):325-339. DOI:10.1245/s10434-012-2513-1.
[16] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 中华肝胆外科杂志,2015, 21(3):145-151. DOI:10.3760/cma.j.issn.1007-8118.2015.03.001.
Chinese Societies ofLiver Cancer, Chinese Anti-Cancer Association;Liver Cancer study Group, Chinese Society of Hepatology, Chinese Medical Association;Chinese Societies of Pathology, Chinese Anti-Cancer Association;et al. Evidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer (2015 edition)[J]. Chin J Hepatobiliary Surg, 2015, 21(3):145-151. DOI:10.3760/cma.j.issn.1007-8118.2015.03.001.
[17] Wang L, Wang W, Yao X, et al. Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion[J]. Oncotarget, 2017, 8(45):79971-79981. DOI:10.18632/oncotarget.20402.
[18] Wang L, Wang W, Rong W, et al. Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion:a non-randomized interventional clinical study[J]. BMC Cancer, 2020, 20(1):614. DOI:10.1186/s12885-020-07087-7.
[19] Mannina EM, Cardenes HR, Lasley FD, et al. Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation:Retrospective Evaluation of Pathologic Response and Outcomes[J]. Int J Radiat Oncol Biol Phys, 2017, 97(5):931-938. DOI:10.1016/j.ijrobp.2016.12.036.
[20] Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs.TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis[J]. J Hepatol, 2017, 67(1):92-99. DOI:10.1016/j.jhep.2017.02.022.
[21] Lee HS, Choi GH, Choi JS, et al. Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy[J]. Ann Surg Oncol, 2014, 21(11):3646-3653. DOI:10.1245/s10434-014-3652-3.
[22] Byun HK, Kim HJ, Im YR, et al. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma[J]. Radiother Oncol, 2019,133:1-8. DOI:10.1016/j.radonc.2018.12.025.
[23] Lee WH, Byun HK, Choi JS, et al. Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria[J]. Radiother Oncol, 2020, 152:1-7. DOI:10.1016/j.radonc.2020.07.046.
[24] Wu ZF, Wang Y, Yang P, et al. Toll-like receptor 4 and its associated proteins as prognostic factors for HCC treated by post-radiotherapy surgery[J]. Oncol Lett, 2018, 15(6):9599-9608. DOI:10.3892/ol.2018.8583.